A phase I study of EDP-938

Trial Profile

A phase I study of EDP-938

Planning
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2017

At a glance

  • Drugs EDP 938 (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Jan 2017 New trial record
    • 06 Jan 2017 According to an Enanta Pharmaceuticals media release, the company expects to initiate this study in the fourth quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top